Американское общество гирудотерапии

Thrombin induced tumour growth - pharmacological control

Research article published in Hamostaseologie (2007)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportРазработка лекарственных препаратовФармакология секрета слюнных желёзNowak G et al. · Hamostaseologie, 2007

Abstract

The central enzyme of blood coagulation, the serine proteinase thrombin, is capable to modify the growth of tumour cells by interaction with protease activated receptors 1 and 4 of the tumour cells. Thrombin is permanently available in tumour micro environment; meizothrombin is generated from prothrombin at a tumour specific activation complex and can influence tumour cell growth via PAR-1 and 7-transdomain protein receptor signalling pathway, too. PEG-coupled direct thrombin inhibitors that possess special pharmacokinetic characteristics and that have been designed for long lasting efficacy in extracellular space, control serine proteinase activity in tumour micro environment and therefore they own a high potential anti-tumour efficacy. In xenographic tumour models this new substance class has shown a significant carcinostatic effect.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeEnglish AbstractJournal Article
Indexed MeSH termsAmino Acid SequenceCell DivisionHirudinsHumansModels, MolecularMolecular Sequence DataNeoplasmsProtein ConformationReceptor, PAR-1Receptors, ThrombinSignal TransductionThrombin

Резюме

The central enzyme of blood coagulation, the serine proteinase thrombin, is capable to modify the growth of tumour cells by interaction with protease activated receptors 1 and 4 of the tumour cells.

Почему это важно для гирудотерапии

This abstract examines how thrombin modifies tumor cell growth through protease-activated receptors (PAR-1 and PAR-4) and tests PEG-coupled direct thrombin inhibitors as a means of controlling thrombin activity in the tumor microenvironment, reporting significant carcinostatic effects in xenographic tumor models. This work is tangentially relevant to the broader pharmacology of thrombin inhibition. However, the abstract makes no mention of hirudin, leeches, or any leech-derived compounds. The study involves a PEG-coupled inhibitor class, not hirudin or related molecules, so the connection to hirudotherapy or the leech secretome is not established by this abstract.

Цитирование

Thrombin induced tumour growth - pharmacological control

Nowak G et al. · Hamostaseologie, 2007

Связанный клинический контекст

Узнайте, как это исследование связано с клинической практикой

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.